These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 17502350)
1. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Shi B; Liang J; Yang X; Wang Y; Zhao Y; Wu H; Sun L; Zhang Y; Chen Y; Li R; Zhang Y; Hong M; Shang Y Mol Cell Biol; 2007 Jul; 27(14):5105-19. PubMed ID: 17502350 [TBL] [Abstract][Full Text] [Related]
2. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140 [TBL] [Abstract][Full Text] [Related]
3. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Hwang C; Giri VN; Wilkinson JC; Wright CW; Wilkinson AS; Cooney KA; Duckett CS Breast Cancer Res Treat; 2008 Jan; 107(2):235-42. PubMed ID: 17453341 [TBL] [Abstract][Full Text] [Related]
4. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305 [TBL] [Abstract][Full Text] [Related]
5. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. Guo Y; Ying L; Tian Y; Yang P; Zhu Y; Wang Z; Qiu F; Lin J FEBS J; 2013 Sep; 280(18):4531-8. PubMed ID: 23815091 [TBL] [Abstract][Full Text] [Related]
6. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Chang CJ; Yang JY; Xia W; Chen CT; Xie X; Chao CH; Woodward WA; Hsu JM; Hortobagyi GN; Hung MC Cancer Cell; 2011 Jan; 19(1):86-100. PubMed ID: 21215703 [TBL] [Abstract][Full Text] [Related]
7. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Lee ST; Li Z; Wu Z; Aau M; Guan P; Karuturi RK; Liou YC; Yu Q Mol Cell; 2011 Sep; 43(5):798-810. PubMed ID: 21884980 [TBL] [Abstract][Full Text] [Related]
8. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. Zeidler M; Kleer CG J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786 [TBL] [Abstract][Full Text] [Related]
9. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648 [TBL] [Abstract][Full Text] [Related]
10. Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. Alves-Guerra MC; Ronchini C; Capobianco AJ Cancer Res; 2007 Sep; 67(18):8690-8. PubMed ID: 17875709 [TBL] [Abstract][Full Text] [Related]
11. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Tonini T; Bagella L; D'Andrilli G; Claudio PP; Giordano A Oncogene; 2004 Jun; 23(28):4930-7. PubMed ID: 15077161 [TBL] [Abstract][Full Text] [Related]
12. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127 [TBL] [Abstract][Full Text] [Related]
13. The Polycomb group protein EZH2 directly controls DNA methylation. Viré E; Brenner C; Deplus R; Blanchon L; Fraga M; Didelot C; Morey L; Van Eynde A; Bernard D; Vanderwinden JM; Bollen M; Esteller M; Di Croce L; de Launoit Y; Fuks F Nature; 2006 Feb; 439(7078):871-4. PubMed ID: 16357870 [TBL] [Abstract][Full Text] [Related]
14. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439 [TBL] [Abstract][Full Text] [Related]
15. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Kleer CG; Cao Q; Varambally S; Shen R; Ota I; Tomlins SA; Ghosh D; Sewalt RG; Otte AP; Hayes DF; Sabel MS; Livant D; Weiss SJ; Rubin MA; Chinnaiyan AM Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11606-11. PubMed ID: 14500907 [TBL] [Abstract][Full Text] [Related]
16. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539 [TBL] [Abstract][Full Text] [Related]
17. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2. Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785 [TBL] [Abstract][Full Text] [Related]
18. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Poulsen TT; Pedersen N; Juel H; Poulsen HS Cancer Gene Ther; 2008 Sep; 15(9):563-75. PubMed ID: 18421308 [TBL] [Abstract][Full Text] [Related]
19. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. Tonini T; D'Andrilli G; Fucito A; Gaspa L; Bagella L J Cell Physiol; 2008 Feb; 214(2):295-300. PubMed ID: 17786943 [TBL] [Abstract][Full Text] [Related]
20. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft. Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]